In December of 2016, the FDA reaffirmed its warning that Actos (a brand name for pioglitazone) is linked to bladder cancer, particularly for people taking large doses or taking the drug for a year or longer.  Actos is commonly prescribed for periods of a year or more to patients suffering from Type II diabetes.  Manufacturers of Actos had hoped that the FDA would retract the link to bladder cancer based on industry-funded research.

Continue Reading: Actos Presents Significant Side Effects